Canada markets close in 5 hours 40 minutes
  • S&P/TSX

    20,919.83
    -8.27 (-0.04%)
     
  • S&P 500

    4,465.44
    -5.93 (-0.13%)
     
  • DOW

    35,148.89
    -145.87 (-0.41%)
     
  • CAD/USD

    0.8089
    +0.0003 (+0.04%)
     
  • CRUDE OIL

    83.10
    +0.82 (+1.00%)
     
  • BTC-CAD

    76,552.38
    +823.38 (+1.09%)
     
  • CMC Crypto 200

    1,447.77
    -3.86 (-0.27%)
     
  • GOLD FUTURES

    1,770.90
    +2.60 (+0.15%)
     
  • RUSSELL 2000

    2,263.11
    -2.55 (-0.11%)
     
  • 10-Yr Bond

    1.5990
    +0.0500 (+3.23%)
     
  • NASDAQ

    14,910.81
    +13.47 (+0.09%)
     
  • VOLATILITY

    17.06
    +0.76 (+4.66%)
     
  • FTSE

    7,187.21
    -46.82 (-0.65%)
     
  • NIKKEI 225

    29,025.46
    +474.56 (+1.66%)
     
  • CAD/EUR

    0.6968
    +0.0001 (+0.01%)
     

U.S. administers about 384.9 million doses of COVID-19 vaccines -CDC

·1 min read
Vaccines are administered to students at Ohio State University

(Reuters) - The United States has administered 384,911,290 doses of COVID-19 vaccines as of Saturday morning and distributed 466,569,635 doses, the U.S. Centers for Disease Control and Prevention said.

Those figures are up from 383,994,877 vaccine doses the CDC said had gone into arms by Sept. 17 out of 464,315,725 doses delivered.

The agency said 211,489,242 people had received at least one dose, while 181,035,022 people were fully vaccinated as of 6 a.m. ET Saturday.

The CDC tally includes two-dose vaccines from Moderna and Pfizer/BioNTech, as well as Johnson & Johnson's JNJ.N one-shot vaccine.

Over 2.11 million people have received an additional dose of either Pfizer or Moderna's vaccine since Aug. 13, when the U.S. authorized a third dose for those with compromised immune systems who are likely to have weaker protection from the two-dose regimens.

(Reporting by Juby Babu in Bengaluru; Editing by Leslie Adler)

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting